Developer docs
API playgroundTry for free, no card

Search company profiles

Seahorse Bioscience

Full company profile

uuid000ar9v

Namestring
Seahorse Bioscience
Legal namestring
Seahorse Bioscience
Websiteurl
seahorsebio.com
Company typeenum
Private
Founded yearint
2000
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNorth Billerica, United States
HQ citystring
North Billerica
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell metabolism analysis, bioenergetics instruments, cell analysis platforms, analytical lab instruments, biomanufacturing consumables
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Cell Analysis Instruments
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Analysis Instruments and Consumables
TypeHardware Sales
Description

Sale of Seahorse XF instruments and associated assay plates, reagents, and consumables for bioenergetics research.

agilent.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Seahorse Bioscience designs, manufactures, and sells the Seahorse XF Platform, a real-time bioenergetics analysis system that measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells. The company also provides associated assay kits, reagents, and consumables for cell metabolism, cancer biology, cardiovascular research, immunology, neurobiology, stem cell biology, and drug discovery applications. Now part of Agilent Technologies' Cell Analysis division, the platform is sold alongside complementary instruments and labware for biological research and drug development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Seahorse Bioscience, now part of Agilent, offers the Seahorse XF Platform as its core product for real-time cell bioenergetics analysis. The platform enables researchers to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells, supporting applications across cell metabolism, cancer biology, cardiovascular research, immunology, neurobiology, stem cell biology, and drug discovery. The technology is used in conjunction with Agilent's cell analysis instruments and tools for measuring cell health, proliferation, migration, and metabolism.

Product and service1 record
1Agilent Seahorse XF Platform
CategoryCell Analysis Instruments
Description

Real-time bioenergetics analysis platform that measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells for academic research institutions, pharmaceutical companies, biotechnology firms, and contract research organizations conducting cell metabolism and drug discovery studies.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest life-sciences analytical instruments and cell-analysis incumbent with broad portfolios spanning flow cytometry, microplate readers, and cell metabolism assays. Directly comparable as the dominant alternative to Agilent/Seahorse in cell-based analytical instrumentation serving pharma and academic research customers.

TypeDirect peer
Description

Specializes in microplate readers, high-content imaging, and cell-based assay instruments used in drug discovery and academic research. Overlaps directly with Seahorse XF in live-cell functional measurement workflows within pharma/biotech screening labs.

TypeDirect peer
Description

Provides cell-based luminescent and fluorescent assays, including metabolism and viability kits, sold into pharma and academic research. Overlaps with Seahorse XF in cell health, cytotoxicity, and metabolic phenotype readouts for drug discovery.

TypeEmerging player
Description

Offers life-science research tools including reagents, proteomics, and cell/gene therapy workflow solutions. Comparable as a research-tools provider with growing cell-analysis offerings relevant to the same pharma/biotech buyer profile as Seahorse.

TypeBroad incumbent
Description

Major bioprocessing and cell-analysis provider serving pharma manufacturing and biotech research with cell-line development and analytical platforms. Comparable in serving cell biology research customers, particularly in upstream bioprocess and cell therapy workflows.

TypeBroad incumbent
Description

Diversified life-sciences and analytical instruments player with cell imaging, microplate, and reagent offerings. Competes with Agilent/Seahorse in life-science research and drug discovery instrumentation budgets.

TypeBroad incumbent
Description

Manufacturer of advanced analytical instruments (mass spectrometry, NMR, microscopy) with growing cell-analysis solutions. Comparable as an analytical-instrument vendor selling into the same academic and pharma research customers.

TypeDirect peer
Description

Specializes in microplate readers with cell metabolism and live-cell kinetic readouts, including oxygen consumption and pH sensing modes. Directly competes with the Seahorse XF platform in metabolic and cell-based assay workflows.

TypeBroad incumbent
Description

Provides flow cytometry, cell sorting, and particle characterization instruments for research and clinical labs. Comparable as a cell-analysis instrumentation peer with overlapping customers in pharma/biotech research.

10Merck KGaA (MilliporeSigma)
TypeBroad incumbent
Description

Life-science tools and reagents giant with cell biology, bioprocessing, and lab instrumentation offerings. Comparable as a broad incumbent serving cell metabolism, cell health, and drug discovery research workflows overlapping with Seahorse XF customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seahorse Bioscience

Cell Analysis Instrumentsseahorsebio.com

Seahorse Bioscience firmographics

Firmographics
Name
Seahorse Bioscience
Legal name
Seahorse Bioscience
Website
https://seahorsebio.com
Company type
Private
Founded year
2000
Operating status
Acquired
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Seahorse Bioscience is headquartered

Location

Headquarters

HQ city
North Billerica
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Seahorse Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Cell Analysis Instruments and Consumables: Sale of Seahorse XF instruments and associated assay plates, reagents, and consumables for bioenergetics research.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Seahorse Bioscience product offering

Product offering

Core offering

Seahorse Bioscience designs, manufactures, and sells the Seahorse XF Platform, a real-time bioenergetics analysis system that measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells. The company also provides associated assay kits, reagents, and consumables for cell metabolism, cancer biology, cardiovascular research, immunology, neurobiology, stem cell biology, and drug discovery applications. Now part of Agilent Technologies' Cell Analysis division, the platform is sold alongside complementary instruments and labware for biological research and drug development.

Product overview

Seahorse Bioscience, now part of Agilent, offers the Seahorse XF Platform as its core product for real-time cell bioenergetics analysis. The platform enables researchers to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells, supporting applications across cell metabolism, cancer biology, cardiovascular research, immunology, neurobiology, stem cell biology, and drug discovery. The technology is used in conjunction with Agilent's cell analysis instruments and tools for measuring cell health, proliferation, migration, and metabolism.

Differentiator

Problem solved

Functional benefit

Products and services

  • Agilent Seahorse XF Platform Real-time bioenergetics analysis platform that measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells for academic research institutions, pharmaceutical companies, biotechnology firms, and contract research organizations conducting cell metabolism and drug discovery studies.

Companies that use Seahorse Bioscience

Customer profile

Segments1 record

Ideal customer profiles1 record

Seahorse Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Seahorse Bioscience partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Seahorse Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific: Largest life-sciences analytical instruments and cell-analysis incumbent with broad portfolios spanning flow cytometry, microplate readers, and cell metabolism assays. Directly comparable as the dominant alternative to Agilent/Seahorse in cell-based analytical instrumentation serving pharma and academic research customers.
  • Sartorius: Major bioprocessing and cell-analysis provider serving pharma manufacturing and biotech research with cell-line development and analytical platforms. Comparable in serving cell biology research customers, particularly in upstream bioprocess and cell therapy workflows.
  • PerkinElmer: Diversified life-sciences and analytical instruments player with cell imaging, microplate, and reagent offerings. Competes with Agilent/Seahorse in life-science research and drug discovery instrumentation budgets.
  • Bruker: Manufacturer of advanced analytical instruments (mass spectrometry, NMR, microscopy) with growing cell-analysis solutions. Comparable as an analytical-instrument vendor selling into the same academic and pharma research customers.
  • Beckman Coulter Life Sciences (Danaher): Provides flow cytometry, cell sorting, and particle characterization instruments for research and clinical labs. Comparable as a cell-analysis instrumentation peer with overlapping customers in pharma/biotech research.
  • Merck KGaA (MilliporeSigma): Life-science tools and reagents giant with cell biology, bioprocessing, and lab instrumentation offerings. Comparable as a broad incumbent serving cell metabolism, cell health, and drug discovery research workflows overlapping with Seahorse XF customers.

Direct peers

  • Molecular Devices (Danaher): Specializes in microplate readers, high-content imaging, and cell-based assay instruments used in drug discovery and academic research. Overlaps directly with Seahorse XF in live-cell functional measurement workflows within pharma/biotech screening labs.
  • Promega: Provides cell-based luminescent and fluorescent assays, including metabolism and viability kits, sold into pharma and academic research. Overlaps with Seahorse XF in cell health, cytotoxicity, and metabolic phenotype readouts for drug discovery.
  • BMG LABTECH: Specializes in microplate readers with cell metabolism and live-cell kinetic readouts, including oxygen consumption and pH sensing modes. Directly competes with the Seahorse XF platform in metabolic and cell-based assay workflows.

Emerging players

  • Bio-Techne: Offers life-science research tools including reagents, proteomics, and cell/gene therapy workflow solutions. Comparable as a research-tools provider with growing cell-analysis offerings relevant to the same pharma/biotech buyer profile as Seahorse.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Seahorse Bioscience social profiles

Digital presence

Seahorse Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seahorse Bioscience leadership team

Management profile

Number of profiles

Profiles4 records

Seahorse Bioscience funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seahorse Bioscience M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seahorse Bioscience

What does Seahorse Bioscience do?

Seahorse Bioscience designs, manufactures, and sells the Seahorse XF Platform, a real-time bioenergetics analysis system that measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in live cells. The company also provides associated assay kits, reagents, and consumables for cell metabolism, cancer biology, cardiovascular research, immunology, neurobiology, stem cell biology, and drug discovery applications. Now part of Agilent Technologies' Cell Analysis division, the platform is sold alongside complementary instruments and labware for biological research and drug development.

Is Seahorse Bioscience a public or private company?

Seahorse Bioscience is a private company. It is classified as corporate owned and is currently acquired.

When was Seahorse Bioscience founded?

Seahorse Bioscience was founded in 2000. It employs 1 to 10 people.

Where is Seahorse Bioscience based?

Seahorse Bioscience is headquartered in North Billerica, United States, in the North America region.

How does Seahorse Bioscience make money?

One revenue line is on record: cell Analysis Instruments and Consumables.

Who are Seahorse Bioscience's main competitors?

Broad incumbents on record are Thermo Fisher Scientific, Sartorius, PerkinElmer, Bruker, Beckman Coulter Life Sciences (Danaher) and Merck KGaA (MilliporeSigma). Direct peers are Molecular Devices (Danaher), Promega and BMG LABTECH. Bio-Techne is listed as an emerging player.

Does Seahorse Bioscience have an API?

No public API is recorded for Seahorse Bioscience.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSeahorse Bioscience XF Technology Reaches 500th Citation in Cancer ResearchSeahorse Bioscience reached its 500th citation in cancer research, with a study published in Scientific Reports evaluating the PI3K inhibitor NVP-BKM120 in acute myeloid leukemia. The study found significant decreases in cellular metabolism, supporting further clinical assessment of the compound.PR NewswireSeahorse XF Cell Energy Phenotype Test Kit Receives Top 10 Innovation Award from The ScientistThe Scientist magazine cited Seahorse Bioscience's XF Cell Energy Phenotype Test Kit as a 2015 Top 10 Innovation. The kit measures mitochondrial respiration and glycolysis, generating an Energy Map in under an hour. Seahorse's XF96 Extracellular Flux Analyzer was also cited as a 2009 Top Ten Innovation.PR NewswireNew XFp Cell Energy Phenotype Test Determines Metabolic PotentialSeahorse Bioscience introduced the XFp Cell Energy Phenotype Test Kit, a one-hour real-time assay that measures mitochondrial and glycolytic activity under basal and stressed conditions. The kit enables direct functional comparisons of metabolic pathways in live cells, helping researchers assess metabolic potential and its role in cancer.PR Newswire APACNew XFp Cell Energy Phenotype Test Determines Metabolic PotentialSeahorse Bioscience introduced the XFp Cell Energy Phenotype Test Kit, a one-hour real-time assay for live cells that measures mitochondrial and glycolytic activity under basal and stressed conditions. The kit enables direct functional comparisons of metabolic pathways, helping researchers assess metabolic potential and its consequences in cancer and other diseases.VC News DailySeahorse Bioscience Swims with $9.4MSeahorse Bioscience, a North Billerica, Massachusetts-based provider of products for biological research and drug discovery, has raised $9.4 million in venture capital from four separate investors according to a new SEC filing. The company manufactures the Seahorse Extracellular Flux (XF) Analyzer, which provides cellular bioenergetic measurement technology for assessing mitochondrial dysfunction in research settings. Founded in 2001, Seahorse Bioscience serves academic institutions, pharmaceutical companies, and biotech organizations with analytical instruments and consumable labware products.